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This study aimed to investigate an unusual case of immature ovarian teratoma with onset of mature glial cells
implanted on the contralateral ovary, a challenge in the diagnosis of the second ovarian tumor. We report the case
of a 31- yr-old woman, who developed at the age of 16 an immature teratoma in the right ovary that was
surgically removed. Six years later mature glial implants were present on the left ovary and six months later at the
level of peritoneum that relapsed after other six months. The patient suffered three surgical resections after the
initial one. Paraffin sections and immunohistochemical examinations using antibodies against glial and neuronal
antigens were performed. In the teratoma, the neuroectodermal tissue expressed Glial fibrillary acidic protein
(GFAP), S100 protein, Epithelial membrane antigen (EMA) and Cytokeratin 34 beta E12 (Ck34beta E12), wheares the
implants expressed only GFAP and S100 protein. The immature teratoma is the rarest type of ovarian teratomas.
Gliomatosis peritonei is an exceptional finding, expecially with onset on the contralaterally ovary. The implant of the
mature glial cells has a high risk of relapse, as seen in our case, thus close follow-up of the patient is necessary.
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The ovarian teratomas are represented by mature, imma-
ture, and monodermal (as struma ovarii, carcinoid tumors,
neural tumors) types. They are considered the most com-
mon germ cells neoplasm. Teratomas comprise a number
of histologic types of tumors, all of which contain mature
or immature tissues of germ cell (pluripotential) origin.
The immature teratoma (IT) is the currently preferred
term for the malignant ovarian teratoma composed of a
mixture of embryonal and adult tissues derived from all
three germ layers. Any type of tissue may be represented.
The main component is usually neurogenic, but mesoder-
mal elements are also common. According to WHO, IT is
defined as a teratoma containing a variable amount of im-
mature embryonal type (generally) neuroectodermal tissue
[1]. Tumor grading is based on the amount of immature
neuroepithelium presence. Regarding the aggressive profile
of the glial cells from an immature teratoma, another* Correspondence: agheorghisan.a@gmail.com
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distribution, and reproduction in any mediumphenomenon might be found: gliomatosis peritonei (GP),
the implant with glial cells.Case presentation
We present a case of a 31 year old female with her med-
ical history. Her family histories were all unremarkable. At
the age of 16 she was accidently (at a routine abdominal
ultrasound) diagnosed with a right ovarian tumor. The
tumor has been removed because of suspected malignant
risk. Pathologic examination showed an immature tera-
toma with glial cells. (Figure 1a) Six years she was asymp-
tomatic then a left ovarian tumor was found because she
accused unspecific pelvic pain which was controlled under
usual analgesics. The tumor was evidenced by computed
tomography and it was completely removed based on
intra-operatory decision. The tumor was yellow, large
(7 by 6 cm) with solid and multi-cystic aspects associ-
ated with another small tumor of 2 cm at the Douglas
level. The intra-operatory pathological exam suggested
an ovarian possible malignant Sertoli-Leydig tumor that
why the ovary was completely removed. Only two years
later the pathological exam was re-analyzed and consid-
ered a mature glial cells implanted into the ovary.
(Figure 1b) Six months later the patient accused persistentBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Microscopic images of resected tumors. a. Immature teratoma of the right ovary HE stain ×4 b. Left ovarian tumor. Ovarian
gliomatosis HE stain ×10 c. Gliomatosis peritonei (first resection) HE stain ×4 d. Gliomatosis peritonei (second resection) HE stain ×4.
Gheorghisan-Galateanu et al. Journal of Ovarian Research 2013, 6:28 Page 2 of 6
http://www.ovarianresearch.com/content/6/1/28abdominal pain and discomfort after meals. The com-
puted tomography showed a tumor of 10 by 6 cm at the
Douglas level up to the sigmoid with cystic and solid com-
ponents, with no evidence of lymph nodes, neither hepatic
metastasis. She suffered the tumor resection at the level of
peritoneum. At that time the diagnosis of peritoneal
carcinomatosis was established and she was treated for six
months with chemotherapy (bleomycin, etoposide and
cisplatin) when she accused again intense abdominal pain
and dysuria, associated with mild elevation of the hepatic
enzymes. The forth surgical procedure was performed be-
cause it was considered a recurrence: exploratory laparot-
omy with viscerolysis. This time the pathological exam
was re-analyzed for all the surgeries and a mature implant
of the teratoma was diagnosed in the second procedure as
well as the diagnosis of gliomatosis peritonei for the last
two procedures was established. (Figure 1c and 1d) The
immunohistochemistry profile was also performed at this
time and it showed positive staining for glial fibrillary
acidic protein (GFAP) in each of the four resections (boths
ovaries, as well as peritoneal tumor). (Figure 2) The stains
were also positive for S100 protein. The immunohisto-
chemical method was an indirect bistadial technique
performed with a polymer based detection system (EnVi-
sion+ Dual Link System-HRP, Dako, Carpinteria, CA). Only
the first tumor, from the right ovary, expressed Epithelial
membrane antigen (EMA) and Ck34beta E 12. IT contains
different types of cells, including the immature glial cells,while the gliomatosis contains only mature glial cells
(Table 1). Since she was ovarectomized, and the malignant
diagnosis was finally excluded she came to our attention to
evaluate the estro-progestative therapy. No estrogen or
progesterone receptors were positive into the tumors so
the therapy was started. She was followed-up for the next
seven years. We consider that life follow-up is necessary.
In addition, at the age of 23 she was diagnosed with pri-
mary hypothyroidism and autoimmune thyroiditis, which
is currently in substitution treatment with L-thyroxine
(75 μg / day). The risk of recurrence in case of gliomatosis
persists also the chance of its malignant transformation is
low. Based on the medical history, probably an adequate
pathology diagnosis at the moment of the second proced-
ure would have saved the second ovary. Yet, the patho-
logical exam is difficult and the pre-operative computed
tomography showed a very large tumor. Also, at that mo-
ment the immunohistochemistry was not routinely
performed. The long medical history of this case highlights
that even in rare situation like this the clinical data and its
analyses may improve the clinical practice and eventually
the patients care.
Discussion and review of the literature
Generally, the teratomas might develop a rather bizarre
behavior, such as others ovarian tumors as those with
virilizating features due the presence of Sertoli-Leydig
cells. The term itself of “teratoma” was derived from the
Figure 2 Glial fibrillary acidic protein (GFAP). a. Immature right ovarian teratoma ×10 b. Mature glial cells in left ovarian gliomatosis ×10
c. Mature glial cells in gliomatosis peritonei (first resection) ×4 d. Mature glial cells in gliomatosis peritonei (second resection) ×4.
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scription of teratoma was made in 1960 by Thürlbeck
and Scully [2].
Teratomas
Teratomas are most frequently found in the gonads
(ovary and testes). Extragonadal teratomas are rare and
arise from midline structures (thyroid, retroperitoneum,
mediastinum, pericardium and brain). Very rarely, tera-
tomas are found in other solid (e.g. breast, parotid gland,
liver) and hollow (e.g. oesophagus, stomach, bladder,
uterine cervix) organs [3]. Teratomas may be benign,
malignant or a component of a mixed germ cell tumor
(GCT) [4]. Mature teratomas are benign tumors, which
are most often composed of derivatives of two or three
germ cell layers. In contrast, immature teratomas are
malignant ovarian tumors, as the present case [5]. IT
represents 3% of all teratomas, 1% of all ovarian cancers
and 20% of malignant ovarian germ cell tumors [6]. It isTable 1 The characteristics of the histological and
imunohistochemical profile of tumors
Immature teratoma Gliomatosis
Type of glial cells Immature Mature
GFAP + +
S100 protein + +
EMA + Negative
Ck 34beta E12 + Negativedefined as a tumor containing immature embryo compo-
nents, usually immature primitive neuroectodermal
tissue. Immature elements represent the evolution of a
malignant clone, and the prognosis relates to the
amount of this component [7]. The lack of 12p amplifi-
cation in immature ovarian teratomas, in contrast to its
presence in other types of malignant ovarian germ cell
tumor, demonstrated a different pathogenesis compared
to other malignant ovarian germ cell tumors [8]. IT of
the ovary is almost always unilateral and is a tumor of
children and adolescents, that occurs essentially during
the first two decades of life [9]. In our case the incidence
was at 16 years of age and also the malignant tumor was
unilateral, the contralateral ovary was affected by the
process of gliomatosis.
Gliomatosis peritonei
Gliomatosis peritonei (GP) can be defined as the meta-
static implantation of glial tissue on surfaces of visceral or
parietal peritoneum. GP is a rare situation, characterized
by the recurrence of peritoneal implants after the surgical
treatment of ovarian teratoma. At histologic analysis, the
implants of gliomatosis peritonei resemble benign mature
glial tissue with delicate fibrillar processes and scattered
supporting cells. Malignant transformation is exceedingly
rare [10]. However, some reports have documented the
rapid recurrence of immature peritoneal implants, as im-
plantation is associated with teratomas of all grades [11].
GFAP is an intermediate filament protein that expresses
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tissue. GFAP immunostain confirmed the glial nature of
the tissue. A strong expression of GFAP often suggests
that tumor cells are mature and well differentiated [12].
The association of GP with the immature teratoma is
rather classical since the majority of cases with GP are
associated with immature ovarian teratoma and extremely
rarely found with mature ovarian teratomas [13]. In the
case we presented, the patient associated ovarian and peri-
toneal gliomatosis, diagnosed six years after the initial
removal of the immature teratoma. Paradoxically, patients
who have immature ovarian teratomas in association with
mature glial implants appear to have a much better prog-
nosis [14]. However, the presence of a secondary tumor,
even with benign cells, complicates the evolution of the
disease because repeated surgery is necessary as well as
ultrasound or computed tomography follow-up over the
time. In our case, the 31 years patient suffered four surgi-
cal procedures. The origin of glial implants in GP and the
factors responsible for the development of GP in associ-
ation with teratomas has been the subject of many studies.
Mechanism of implantation
The mechanism of implantation is unknown and two
hypotheses to explain the origin of GP have been pro-
posed. The first hypothesis suggests that GP is genetic-
ally related to the associated teratoma, and the cells
from the primary tumor relocated through a spontan-
eous or surgical capsular defect or disseminated via
angiolymphatic channels [15]. Capsular defects have
been described in resected teratomas and in some
instances, teratomatous tissue has been observed pro-
truding through these defects [16]. In support of lymph-
atic dissemination, mature glial tissue has been found in
mesenteric, para-aortic, and retroperitoneal lymph nodes
in association with immature teratomas, in the presence
or the absence of GP [17]. The second hypothesis, who
has more supporters, suggested that glial foci are genet-
ically unrelated to the associated teratoma, glial implants
developing from normal cells in the peritoneum or sub-
jacent mesenchyme. They presumably originate in pluri-
potent Müllerian stem cells, which have undergone a
metaplastic process in response to an unknown neoplas-
tic stimulus [18]. The implant cell needs a favorable
matrix environment in order to survive.
Associated or independent?
To determine whether glial implants are genetically re-
lated to the associated ovarian teratoma or whether
they arise independently, it was studied the genetic pro-
file of ovarian teratomas. Approximately 65% of terato-
mas are derived from a single germ cell after the first
meiotic division with subsequent failure of meiosis 2 or
endoreduplication of a haploid ovum [19]. Molecularstudies suggest that ovarian teratoma and GP are genetic-
ally distinct (multiple independent tumors rather than re-
lapse or metastasis). Some studies have demonstrated that
all implants and normal tissue showed heterozygosity at
each of the three microsatellite loci on different chromo-
somes, whereas teratoma showed homozygosity at same
microsatellite loci, indicating that glial implants in GP
often arise from cells the peritoneum, and not associated
with ovarian teratoma [20]. Another study concluded that
GP is probably derived from metaplasia of submesothelial
cells [21]. The remarkable ability of stem cells derived
from various organs to differentiate along divergent path-
ways has been the subject of several articles, including
studies demonstrating that bone marrow-derived stem
cells can undergo glial differentiation [22]. A stem cell’s
microenvironment can induce a specific differentiation
pathway, and it is possible that some teratomas with an
abundant glial component secrete factors that induce glial
differentiation in the peritoneum. Murine astrocyte cells
and teratocarcinoma cell lines have been shown to secrete
β-nerve growth factor in vitro [23]. GP has been described
in children without teratomas who have had ventriculo-
peritoneal shunts placed early in infancy. In this case,
neural growth factors, normally present in cerebrospinal
fluid, may enter the peritoneum through the shunt and
induce glial differentiation in the same manner [24].
Treatment and prognosis
The treatment of IT and GP is complete surgical resec-
tion, also useful for identifying the presence or absence
of malignant lesions and for preventing malignancy
transformation of the GP residual fragments. Because
the lesions are extensive, complete excision is usually
very difficult. Potential for recurrence is high, and there-
fore requires a careful monitoring of residual lesions
using scanning imaging such as computed tomography.
In our case, the diagnosis of GP was difficult since it
started as a contralateral ovarian tumor diagnosed with
MRI. The prognosis of IT heavily depends on the FIGO
stage [25]. It is influenced by several factors, such as
tumor grade, growth pattern, capsular rupture and
vascular invasion. It is important to separate from this
group the teratomas that also have a yolk sac tumor
pattern, since the prognosis substantially decreases
under these circumstances [26].
Recent study indicates that Oct4 might serve as a prom-
ising biomarker for the diagnosis of highly malignant cases
of immature teratoma because Oct4 expression was exclu-
sively detected in immature neuroepithelium of high-grade
immature teratomas [27]. Immature ovarian teratoma usu-
ally shows only relatively minor cytogenetic abnormalities,
in contrast to the other forms of malignant ovarian germ
cell tumors, with increasing abnormalities as the grade of
the immaturity becomes higher [28]. Some authors believe
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ence of aneuploidy. Indeed, immature teratomas grade 1
and 2 are diploid in 90% of cases, while most teratomas
grade 3 are aneuploid (66% of cases). In addition, karyotype
abnormalities are more frequent in grade 3 [29].Conclusion
Immature teratoma is a malignant tumor of the first de-
cades of life. In some cases, the difficult evolution comes
from the association with glial implants, as seen in our
case at the contralateral ovary, and the peritoneal level.
The glial features are reflected by positive GFAP and
S100 protein in gliomatosis, as well as in the primary
tumor. In patients with immature teratoma and no evi-
dence of disease recurrence, surgery alone is an effective
treatment of the primary tumor. In immature teratoma
associated with gliomatosis peritonei, combined chemo-
therapy is recommended. Surgery and chemotherapy can
give longer survival even in recurrent disease. MRI may
also have a role in monitoring patients for many years as
a safe, reproducible and accurate technique for patients
who associated GP.Consent
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for publication of this Case report and any accompany-
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